All In Biotech

Drug Trial Radar · NCT06012695

NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma

A Phase Ib/II, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

79

Planned (sponsor's estimate)

Start

Aug 11, 2023

Primary completion

May 30, 2028

Study completion Sep 30, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 25, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.

Conditions

  • Malignant Neoplasm
  • Malignant Neoplasm of Brain

Interventions

  • NBM-BMX CapsuleDrug

    Each capsule contains 100 mg of the active ingredient.

  • TemozolomideDrug

    TMZ will be administered orally at a 75 mg/m2 dose daily during concomitant therapy. In the maintenance period, days 1-5 of each cycle will be administered 150-200 mg/m2.

  • Standard radiotherapyRadiation

    A total dose of 60 Gy will be administered in 6 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. [Arm A, Phase Ib] Frequency of dose-limiting toxicity (DLT) at each dose levelTime frame: up to 28 days
  2. [Arm B, Phase Ib] Frequency of dose-limiting toxicity (DLT) at each dose levelTime frame: up to 10 weeks
  3. [Arm B, Phase II] Progression-free survival rate at 6 months (PFS6)Time frame: up to 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Not yet recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • Koo Foundation Sun Yat-Sen Cancer Center

    Taipei, Taiwan · Recruiting

  • Linkou Chang-Gung Memorial Hospital

    Taoyuan City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.